Barely Significant
← all phrases

“borderline non-significant”

435 sentences · 435 papers · 642 search hits before verification

In the literature

borderline non-significantp = 0.081.6× alpha
CSS mice had higher liver expression of Tdo1 (t (10) = 2.4, p < 0.04), Ido2 (t (10) = 2.6, p < 0.03), Tdo2 (t (10) = 2.6, p < 0.03), Kynu (t (10) = 2.3, p < 0.05) and 3-Haao (t (10) = 3.4, p < 0.007), and a borderline non-significant increase in Kmo (p = 0.08) ( Fig. 3 B).
borderline non-significantp < 0.081.6× alpha
This potential indication of reduced task motivation was investigated using additional measures: for mean post-reinforcement latency (s) there was a borderline non-significant AS × genotype interaction [ F (1, 37) = 3.3, p < 0.08]: HET-AS mice (6.1 ± 0.8) had a longer post-reinforcement latency than HET-No-AS mice [4.0 ± 0.4; t (19) = 2.4, p < 0.03].
borderline non-significantp = 0.0851.7× alpha
Although rutin treatment at a dose of 100 mg produced a borderline non-significant decrease in the lung index by 15.67% ( p = 0.085), the treatment with the higher dose was able to reduce the lung index significantly by 30.41% ( p = 0.001) compared to the BLM-intoxicated group ( Figure 5A ).
borderline non-significantp = 0.0851.7× alpha
Post-hoc analysis at 4 weeks demonstrated a significant difference between defects treated with the carp collagen membrane alone and those treated with Bio-Oss® + carp collagen membrane (p = 0.011), and a borderline non-significant difference between the carp collagen membrane alone and the Bio-Oss® + Bio-Gide® group (p = 0.085).
borderline non-significantp = 0.0881.8× alpha
Age ≥ 80 years was an independent predictor of mortality (HR 2.56, 95 % CI1.69–3.87, p < 0.001), a borderline non-significant predictor of overall bleeding (HR 1.38, 95 %CI 0.95–2.00, p = 0.088), and a significant predictor of non-access site bleeding (HR 2.26, 95 %CI 1.46–3.51, p < 0.001).
borderline non-significantP = .0881.8× alpha
Statistically significant changes were observed during the study treatment only for improved emotional functioning ( P = .014), a borderline non-significant worsening of appetite loss ( P = .088), as assessed by the EORTC QLQ C30, and an increase in alopecia ( P = .012), as evaluated by the LC13.